Compounds > chitosan
Page last updated: 2024-08-25

chitosan and glucagon-like peptide 1

chitosan has been researched along with glucagon-like peptide 1 in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's7 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Alameh, M; Buschmann, MD; Jean, M; Merzouki, A1
Alameh, M; Buschmann, MD; Darras, V; De Jesus, D; Jean, M; Lavertu, M; Merzouki, A; Nelea, M; Thibault, M1
Cheng, RS; Chiang, MT; Hsieh, YL; Yao, HT1
Chiang, MT; Chiu, CY; Huang, YW; Liu, SH; Wu, CT1
Araújo, F; Fonte, P; Granja, PL; Hirvonen, JT; Mäkilä, EM; Salonen, JJ; Santos, HA; Sarmento, B; Shahbazi, MA; Shrestha, N1
Araújo, F; Granja, PL; Herranz-Blanco, B; Hirvonen, JT; Liu, D; Mäkilä, EM; Salonen, JJ; Santos, HA; Sarmento, B; Shahbazi, MA; Shrestha, N1
Airavaara, M; Araújo, F; Gomes, MJ; Hirvonen, J; Kauppinen, EI; Mäkilä, E; Raula, J; Salonen, J; Santos, HA; Sarmento, B; Shahbazi, MA; Shrestha, N1

Other Studies

7 other study(ies) available for chitosan and glucagon-like peptide 1

ArticleYear
Effective and safe gene-based delivery of GLP-1 using chitosan/plasmid-DNA therapeutic nanocomplexes in an animal model of type 2 diabetes.
    Gene therapy, 2011, Volume: 18, Issue:8

    Topics: Animals; Chitosan; Diabetes Mellitus, Experimental; Genetic Therapy; Genetic Vectors; Glucagon-Like Peptide 1; Insulin; Nanoconjugates; Plasmids; Rats; Rats, Zucker

2011
Chitosan-based therapeutic nanoparticles for combination gene therapy and gene silencing of in vitro cell lines relevant to type 2 diabetes.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2012, Jan-23, Volume: 45, Issue:1-2

    Topics: Acetylation; Caco-2 Cells; Chemical Phenomena; Chitosan; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Gene Silencing; Gene Transfer Techniques; Genetic Therapy; Glucagon-Like Peptide 1; Hep G2 Cells; HT29 Cells; Humans; Molecular Weight; Nanoparticles; Particle Size; Recombinant Fusion Proteins; Recombinant Proteins; RNA, Small Interfering

2012
Chitosan reduces plasma adipocytokines and lipid accumulation in liver and adipose tissues and ameliorates insulin resistance in diabetic rats.
    Journal of medicinal food, 2012, Volume: 15, Issue:5

    Topics: Adiponectin; Adipose Tissue; Animals; Biological Products; Blood Glucose; Chitosan; Cholesterol; Diabetes Mellitus, Experimental; Glucagon-Like Peptide 1; Hypoglycemic Agents; Inflammation; Insulin; Insulin Resistance; Interleukin-6; Lipid Metabolism; Liver; Male; PPAR alpha; Rats; Rats, Sprague-Dawley; Triglycerides; Tumor Necrosis Factor-alpha

2012
Low molecular weight chitosan accelerates glucagon-like peptide-1 secretion in human intestinal endocrine cells via a p38-dependent pathway.
    Journal of agricultural and food chemistry, 2013, May-22, Volume: 61, Issue:20

    Topics: Cell Line; Chitosan; Dose-Response Relationship, Drug; Enteroendocrine Cells; Gene Expression; Glucagon-Like Peptide 1; Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Signaling System; Molecular Weight; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Proglucagon; RNA, Messenger

2013
The impact of nanoparticles on the mucosal translocation and transport of GLP-1 across the intestinal epithelium.
    Biomaterials, 2014, Volume: 35, Issue:33

    Topics: Biocompatible Materials; Caco-2 Cells; Cell Survival; Chitosan; Drug Carriers; Glucagon-Like Peptide 1; HT29 Cells; Humans; Intestinal Mucosa; Mucous Membrane; Nanoparticles; Nanotechnology; Particle Size; Permeability; Polyglactin 910; Porosity; Silicon

2014
Microfluidic Assembly of a Multifunctional Tailorable Composite System Designed for Site Specific Combined Oral Delivery of Peptide Drugs.
    ACS nano, 2015, Aug-25, Volume: 9, Issue:8

    Topics: Caco-2 Cells; Cell Survival; Cell-Penetrating Peptides; Chitosan; Coculture Techniques; Dipeptidyl Peptidase 4; Drug Compounding; Drug Delivery Systems; Drug Liberation; Drug Synergism; Glucagon-Like Peptide 1; HT29 Cells; Humans; Hydrogen-Ion Concentration; Kinetics; Methylcellulose; Microfluidics; Nanoparticles; Permeability; Polyglactin 910; Porosity; Silicon

2015
Oral hypoglycaemic effect of GLP-1 and DPP4 inhibitor based nanocomposites in a diabetic animal model.
    Journal of controlled release : official journal of the Controlled Release Society, 2016, 06-28, Volume: 232

    Topics: Administration, Oral; Animals; Blood Glucose; Chitosan; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon-Like Peptide 1; Intestine, Small; Methylcellulose; Nanocomposites; Nanoparticles; Rats, Wistar; Silicon

2016